Blueprint Medicines Corp Equity-NMS: BPMC

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$129.46

1Y :

42.56%

5Y :

35.39%

What is the share price of Blueprint Medicines Corp today?

Blueprint Medicines Corp (BPMC) share price as of October 5, 2025, is $129.46. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Blueprint Medicines Corp?

Yes, Indian Investors can invest in the Blueprint Medicines Corp (BPMC) Share by opening an international trading account with Angel One.

How can I purchase Blueprint Medicines Corp shares in India?

Purchasing Blueprint Medicines Corp (BPMC) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Blueprint Medicines Corp (BPMC) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Blueprint Medicines Corp?

Yes, you can purchase fractional shares of Blueprint Medicines Corp (BPMC) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Blueprint Medicines Corp?

The market capitalization of Blueprint Medicines Corp on October 5, 2025, is $0.

In which sector Blueprint Medicines Corp belongs?

Blueprint Medicines Corp operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Blueprint Medicines Corp stocks?

In order to invest in Blueprint Medicines Corp (BPMC) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.